Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1 3,7.1 9,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles

Journal of Medicinal Chemistry

Volumn 55, Issue 1, 2012, Pages 449-464

  Breslin, Henry J ^a   Lane, Brandon M ^a   Ott, Gregory R ^a   Ghose, Arup K ^a   Angeles, Thelma S ^a   Albom, Mark S ^a   Cheng, Mangeng ^a   Wan, Weihua ^a   Haltiwanger, R Curtis ^a   Wells Knecht, Kevin J ^a   Dorsey, Bruce D ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(2,5 DICHLOROPYRIMIDIN 4 YL)(2 METHOXY 5 VINYLPHENYL)AMINE; (2,5 DICHLOROPYRIMIDIN 4 YL)[2 (PROPANE 2 SULFONYL) 5 VINYLPHENYL]AMINE; (3 BROMOPHENYL)(2,5 DICHLOROPYRIMIDIN 4 YL)AMINE; (5 BROMO 2 METHOXYPHENYL)(2,5 DICHLOROPYRIMIDIN 4 YL)AMINE; 2 METHOXY 5 VINYLPHENYLAMINE; 4 BROMO 2 (2,5 DICHLOROPYRIMIDIN 4 YLAMINO)BENZOIC ACID METHYL ESTER; [(2,5 DICHLOROPYRIMIDIN 4 YL) 3 VINYLPHENYL]AMINE; [5 BROMO 2 (PROPANE 2 SULFONYL)PHENYL](2,5 DICHLOROPYRIMIDIN 4 YL)AMINE; ANAPLASTIC LYMPHOMA KINASE; INSULIN RECEPTOR KINASE; MACROCYCLIC COMPOUND; N (2)(3 BROMO 4 MORPHOLIN 4 YLPHENYL) 5 CHLORO N (4) 3 VINYLPHENYL)PYRIMIDINE 2,4 DIAMINE; N (2)[3 BROMO 4 (2 PYRROLIDIN 1 YLETHOXY)PHENYL] 5 CHLORO N (4)(3 VINYLPHENYL)PYRIMIDINE 2,4 DIAMINE; N (2)[3 BROMO 4 (4 METHYLPIPERAIN 1 YL)PHENYL] 5 CHLORO N (4)(3 VINYLPHENYL)PYRIMIDINE 2,4 DIAMINE; N (2)[3 BROMO 4 MORPHOLIN 4 YLPHENYL] 5 CHLORO N (4)(2 METHOXY 5 VINYLPHENYL)PYRIMIDINE 2,4 DIAMINE; N (4)(3 BROMOPHENYL) 5 CHLORO N (2)(3 VINYLPHENYL)PYRIMIDINE 2,4 DIAMINE; N (4)(5 BROMO 2 METHOXYPHENYL] 5 CHLORO N (2)(3 VINYLPHENYL) PYRIMIDINE 2,4 DIAMINE; N [2 (2,5 DICHLOROPYRIMIDIN 4 YL AMINO) 4 VINYLPHENYL] N METHYL METHANESULFONAMIDE; N [4 BROMO 2 (2,5 DICHLOROPYRIMIDIN 4 YLAMINO)PHENYL] N METHYLMETHANESULFONAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME CONFORMATION; ENZYME INHIBITION; IC 50; IN VITRO STUDY; INHIBITION KINETICS;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, INSULIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84855857003     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201333e     Document Type: Article

References (30)

1. American Cancer Society. http://www.cancer.org.
2. CANCER: Principles and Practice of Oncology, 8 th ed.; Devita, V. T., Jr., Lawrence, T. A., Rosenberg, S. A., Eds.; Lippincott, Williams & Wilkins: Philadelphia, PA, 2008.
3. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9 (1) 28-39
4. Fedorov, O.; Mueller, S.; Knapp, S. The (un)targeted cancer kinome Nat. Chem. Biol. 2010, 6 (3) 166-169
5. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome Science 2002, 298, 1912-1934
6. Lu, K. V.; Jong, K. A.; Kim, G. Y.; Singh, J.; Dia, E. Q.; Yoshimoto, K.; Wang, M. Y.; Cloughesy, T. F.; Nelson, S. F.; Mischel, P. S. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin J. Biol. Chem. 2005, 280, 26953-26964
7. George, R. E.; Sanda, T.; Hanna, M.; Froehling, S.; Luther, W., II; Zhang, J.; Ahn, Y.; Zhou, W.; London, W. B.; McGrady, P.; Xue, L.; Zozulya, S.; Gregor, V. E.; Webb, T. R.; Gray, N. S.; Gilliland, D. G.; Diller, L.; Greulich, H.; Morris, S. W.; Meyerson, M.; Look, A. Activating mutations in ALK provide a therapeutic target in neuroblastoma Nature 2008, 455, 975-978
8. Morris, S. W.; Kirstein, M. N.; Valentine, M. B.; Dittmer, K. G.; Shapiro, D. N.; Saltman, D. L.; Look, A. T. Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkins Lymphoma Science 1994, 263, 1281-1284
9. Palmer, R. H.; Vernersson, E.; Grabbe, C.; Hallberg, B. Anaplastic Lymphoma Kinase: Signalling in Development and Disease Biochem. J. 2009, 420, 345-361
10. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.-i.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 2007, 448, 561-566
11. Koivunen, J. P.; Mermel, C.; Zejnullahu, K.; Murphy, C.; Lifshits, E.; Holmes, A. J.; Choi, H. G.; Kim, J.; Chiang, D.; Thomas, R.; Lee, J.; Richards, W. G.; Sugarbaker, D. J.; Ducko, C.; Lindeman, N.; Marcoux, J. P.; Engelman, J. A.; Gray, N. S.; Lee, C.; Meyerson, M.; Jaenne, P. A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin. Cancer Res. 2008, 14, 4275-4283
12. Elenitoba-Johnson, K. S. J.; Crockett, D. K.; Schumacher, J. A.; Jenson, S. D.; Coffin, C. M.; Rockwood, A. L.; Lim, M. S. Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 7402-7407
13. Christensen, J. G.; Zou, H. Y.; Arango, M. E.; Li, Q.; Lee, J. H.; McDonnell, S. R.; Yamazaki, S.; Alton, G. R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther. 2007, 6, 3314-3322
14. Zou, H. Y.; Li, Q.; Lee, J. H.; Arango, M. E.; McDonnell, S. R.; Yamazaki, S.; Koudriakova, T. B.; Alton, G.; Cui, J. J.; Kung, P.-P.; Nambu, M. D.; Los, G.; Bender, S. L.; Mroczkowski, B.; Christensen, J. G. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms Cancer Res. 2007, 67, 4408-4417
15. An Investigational Drug, PF-02341066 Is Being Studied versus Standard of Care in Patients with Advanced Non-Small Cell Lung Cancer with a Specific Gene Profile Involving the Anaplastic Lymphoma Kinase (ALK) Gene. http://www.clinicaltrials.gov/ct2/show/NCT00932893.
16. Milkiewicz, K. L.; Ott, G. R. Inhibitors of anaplastic lymphoma kinase: a patent review Expert Opin. Ther. Pat. 2010, 20 (12) 1653-1681
17. Mesaros, E. F.; Burke, J. P.; Parrish, J. D.; Dugan, B. J.; Anzalone, A. V.; Angeles, T. S.; Albom, M. S.; Aimone, L. D.; Quail, M. R.; Wan, W.; Lu, L.; Huang, Z.; Ator, M. A.; Ruggeri, B. A.; Cheng, M.; Ott, G. R.; Dorsey, B. D. Novel 2,3,4,5-tetrahydro-benzo[ d ]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models Bioorg. Med. Chem. Lett. 2011, 21 (6) 463-466
18. Marsault, E.; Peterson, M. L. Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery J. Med. Chem. 2011, 54, 1961-2004
19. Williams, A. D.; Lee, A.C.-H.; Blanchard, S.; Poulsen, A.; Teo, E. L.; Nagaraj, H.; Tan, E.; Chen, D.; Williams, M.; Sun, E. T.; Goh, K. C.; Ong, W. C.; Goh, S. K.; Hart, S.; Jayaraman, R.; Pasha, M. K.; Ethirajulu, K.; Wood, J. M.; Dymock, B. W. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3, 5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma J. Med. Chem. 2011, 54, 4638-4658
20. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery-an underexploited structural class Nat. Rev. 2008, 7, 608-624
21. Freyne, E. J. E.; Willems, M.; Embrechts, W. C. J.; Van Emelen, K.; Van Brandt, S. F. A.; Rombouts, F. J. R. 2,4 (4,6) Pyrimidine Derivatives. WO 2006061415, June 15, 2006.
22. Bossi, R. T.; Saccardo, M. B.; Ardini, E.; Menichincheri, M.; Rusconi, L.; Magnaghi, P.; Orsini, P.; Avanzi, N.; Lombardi Borgia, A.; Nesi, M.; Bandiera, T.; Fogliatto, G.; Bertrand, J. A. Crystal structures of anaplastic lymphoma kinase in complex with ATP-competitive inhibitors Biochemistry 2010, 49 (32) 6813-6825
23. Combs, A. P.; Sparks, R. B.; Yue, E. W.; Feng, H.; Bower, M. J.; Zhu, W. Macrocyclic Compounds as Kinase Inhibitors and Their Preparation, Pharmaceutical Compositions and Their Use in the Treatment of JAK/ALK-Associated Diseases. WO 2009132202, October 29, 2009.
24. Mulvihill, M. J.; Ji, Q.-S.; Coate, H. R.; Cooke, A.; Dong, H.; Feng, L.; Foreman, K.; Rosenfeld-Franklin, M.; Honda, A.; Mak, G.; Mulvihill, K. M.; Nigro, A. L.; OConnor, M.; Pirrit, C.; Steinig, A. G.; Siu, K.; Stolz, K. M.; Sun, Y.; Tavares, P. A. R.; Yao, Y.; Gibson, N. W. Novel 2-phenylquinolin-7-yl- derived imidazo[1,5- a ]pyrazines as potent insulin-like growth factor (IGF-IR) inhibitors Bioorg. Med. Chem. 2008, 16, 1359-1375
25. Lee, C. C.; Jia, Y.; Li, N.; Sun, X.; Ng, K.; Ambing, E.; Gao, M. Y.; Hua, S.; Chen, C.; Kim, S.; Michellys, P. Y.; Lesley, S. A.; Harris, J.; Spraggon, G. Crystal structure of the anaplastic lymphoma kinase (Alk) catalytic domain Biochem. J. 2010, 430, 425-437
26. Ghose, A. K.; Herbertz, T.; Pippin, D. A.; Salvino, J. M.; Mallamo, J. P. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery J. Med. Chem. 2008, 51, 5149-5171
27. Beruben, D.; Marek, I.; Normant, J. F.; Platzer, N. Stereodefined substituted cyclopropyl zinc reagents from gem-bismetallics J. Org. Chem. 1995, 60, 2488-2501
28. Hamersma, J. W.; Snyder, E. I. Diimide reductions using potassium azodicarboxylate J. Org. Chem. 1965, 30, 3985-3988
29. Angeles, T. S.; Steffler, C.; Bartlett, B. A.; Hudkins, R. L.; Stephens, R. M.; Kaplan, D. R.; Dionne, C. A. Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity Anal. Biochem. 1996, 236 (1) 49-55
30. Rotin, D.; Margolis, B.; Mohammadi, M.; Daly, R. J.; Daum, G.; Li, N.; Fischer, E. H.; Burgess, W. H.; Ullrich, A.; Schlessinger, J. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase Cγ EMBO J. 1992, 11 (2) 559-567